Literature DB >> 10458991

Initial and innate responses to viral infections--pattern setting in immunity or disease.

C A Biron1.   

Abstract

Host responses to infectious challenges include initial events elicited directly by agent structures distinct from host determinants, activation of innate immune system components by the products of initial events, and the shaping of downstream adaptive immunity by these initial/innate responses. The picture emerging from viral infections is that viral structures interact with intracellular signaling pathways to induce expression of the type 1 interferons, IFN-alpha/beta. In addition to mediating direct antiviral effects, these cytokines play dominant roles in regulating innate and adaptive immune responses to infection. In particular, IFN-alpha/beta acts to inhibit interleukin-12 (IL-12) expression and IL-12 activation of innate natural killer (NK) cell IFN-alpha production, while inducing NK cell cytotoxicity and proliferation, and promoting adaptive T cell IFN-alpha responses. Although certain viral infections do elicit initial/innate IL-12 and NK-cell-produced IFN-alpha, endogenous IFN-alpha/beta also controls the magnitudes of these responses. Thus, the pathways activated, to dominantly regulate innate and adaptive immune responses during viral infections, are being defined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458991     DOI: 10.1016/s1369-5274(99)80066-6

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  79 in total

Review 1.  Innate immune control of HIV.

Authors:  Mary Carrington; Galit Alter
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

Review 2.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

3.  Inflammatory IL-15 is required for optimal memory T cell responses.

Authors:  Martin J Richer; Lecia L Pewe; Lisa S Hancox; Stacey M Hartwig; Steven M Varga; John T Harty
Journal:  J Clin Invest       Date:  2015-08-04       Impact factor: 14.808

4.  Activation of human macrophages by bacterial components relieves the restriction on replication of an interferon-inducing parainfluenza virus 5 (PIV5) P/V mutant.

Authors:  Caitlin M Briggs; Robert C Holder; Sean D Reid; Griffith D Parks
Journal:  Microbes Infect       Date:  2010-12-24       Impact factor: 2.700

5.  Social disruption induced priming of CNS inflammatory response to Theiler's virus is dependent upon stress induced IL-6 release.

Authors:  E G Vichaya; E E Young; M A Frazier; J L Cook; C J Welsh; M W Meagher
Journal:  J Neuroimmunol       Date:  2011-10-13       Impact factor: 3.478

6.  Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism.

Authors:  K D Ryman; W B Klimstra; K B Nguyen; C A Biron; R E Johnston
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 7.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 8.  Decoding the complexity of type I interferon to treat persistent viral infections.

Authors:  Elizabeth B Wilson; David G Brooks
Journal:  Trends Microbiol       Date:  2013-11-08       Impact factor: 17.079

9.  Cerebral expression of interleukin-12 induces neurological disease via differential pathways and recruits antigen-specific T cells in virus-infected mice.

Authors:  Markus Hofer; Jürgen Hausmann; Peter Staeheli; Axel Pagenstecher
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections.

Authors:  Elina I Zuniga; Li-Ying Liou; Lauren Mack; Marilyn Mendoza; Michael B A Oldstone
Journal:  Cell Host Microbe       Date:  2008-10-16       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.